Nanobody-based individualized AXL targeting to reserve immune suppression and overcome therapy resistance in Acute Myeloid Leukemia

De Veirman, Kim (Administrative Promotor)

Basis (bio)-medische wetenschappen

Acroniem	ANI265
Status	Geëindigd
Effectieve start/einddatum	7/09/20 → 15/09/21

Dataset of AXL-specific single domain antibodies show diagnostic potential and anti-tumor activity in Acute Myeloid Leukemia
Vandewalle, N. (Creator), Satilmis, H. (Creator), Verheye, E. (Creator), Wang, Y. (Creator), De Groof, T. (Creator), Bridoux, J. (Creator), Kerre, T. (Creator), De Beule, N. (Creator), De Becker, A. (Creator), De Bruyne, E. (Creator), Menu, E. (Creator), Vanderkerken, K. (Creator), Breckpot, K. (Creator), Devoogdt, N. (Creator) & De Veirman, K. (Creator), Theranostics, 15 apr. 2024
DOI: 10.7150/thno.91456, https://zenodo.org/records/15111364
Dataset